Moderna (NASDAQ:MRNA) Shares Down 7.6% – Here’s Why

Shares of Moderna, Inc. (NASDAQ:MRNA) traded down 7.6% during mid-day trading on Friday . The company traded as low as $49.58 and last traded at $49.75. 3,560,598 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 12,508,803 shares. The stock had previously closed at $53.83.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Settlement clears legal overhang: Moderna reached deals to resolve long?running LNP patent litigation, which investors interpret as removing a major uncertainty that had been capping the stock. The market initially reacted positively to news the dispute is resolved. Moderna to pay up to $2.25B to end mRNA vaccine patent fight Moderna fronts $950M to settle yearslong COVID patent litigation
• Positive Sentiment: Bullish options flow: Unusually heavy call buying (112,509 calls, ~32% above typical volume) signals short?term bullish positioning by traders and could support intraday upside if flows continue. (No external link provided)
• Positive Sentiment: Retail interest and momentum: Retail chatter and short?term momentum have helped lift the stock recently (double?digit weekly moves and large YTD gains cited by coverage), which can amplify volatility around news. Reddit Traders Are Cheering Moderna While Bears Watch the Cash Burn
• Neutral Sentiment: Analyst and narrative pieces: Several outlets are revisiting Moderna’s investment case (pipeline potential, oncology vaccine upside) and whether today’s price is a buying opportunity — useful context but not immediate catalysts. Moderna Stock (MRNA): Is It a Buy Now?
• Neutral Sentiment: Market bounce context: Coverage grouping Moderna with other volatile names notes technical bounces and differing Wall Street views — helpful for traders but mixed for longer?term investors. These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next
• Negative Sentiment: Regulatory uncertainty: Reports highlighting recent FDA reversals and tougher scrutiny on new drug applications have increased investor concern that future approvals (e.g., respiratory or flu programs) could face delays or setbacks. That regulatory risk is pressuring the stock today. FDA reversals leave investors worrying about the fates of other experimental drugs
• Negative Sentiment: Cash/cost impact of the settlement: While the settlement removes legal overhang, it carries a material cash burden (Moderna may pay up to ~$2.25B and is fronting $950M), which renews concerns about cash burn and near?term finances—an important negative for fundamental investors. Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology

Analyst Ratings Changes

Several analysts have recently issued reports on MRNA shares. Morgan Stanley set a $30.00 price objective on Moderna in a research report on Monday, February 16th. Jefferies Financial Group set a $37.00 price target on shares of Moderna and gave the stock a “hold” rating in a report on Tuesday. Berenberg Bank set a $28.00 price objective on shares of Moderna in a research note on Monday, November 17th. BMO Capital Markets raised shares of Moderna from a “market perform” rating to a “buy” rating in a research note on Monday, January 12th. Finally, Citigroup reissued a “neutral” rating on shares of Moderna in a research note on Monday, February 16th. Two investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $32.33.

Moderna Price Performance

The company’s fifty day moving average is $43.13 and its two-hundred day moving average is $32.26. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29. The firm has a market cap of $20.74 billion, a price-to-earnings ratio of -7.22 and a beta of 1.29.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.79) by $0.68. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The firm had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. During the same period in the prior year, the firm earned ($2.91) EPS. The firm’s quarterly revenue was down 33.2% compared to the same quarter last year. Equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 160,009 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president directly owned 1,457,427 shares of the company’s stock, valued at approximately $71,180,734.68. The trade was a 9.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 23,853 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This represents a 85.87% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 184,366 shares of company stock valued at $8,531,936. Insiders own 10.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Norges Bank bought a new position in Moderna during the 2nd quarter valued at $94,910,000. Vanguard Group Inc. increased its position in shares of Moderna by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock worth $1,150,743,000 after purchasing an additional 1,312,192 shares during the last quarter. Legal Advantage Investments Inc. acquired a new stake in shares of Moderna in the 3rd quarter valued at about $1,244,000. Letko Brosseau & Associates Inc. raised its stake in shares of Moderna by 2.4% in the 2nd quarter. Letko Brosseau & Associates Inc. now owns 918,190 shares of the company’s stock valued at $25,333,000 after purchasing an additional 21,765 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Moderna during the third quarter worth about $2,351,000. 75.33% of the stock is owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.